ArticleHeliyon2023
A selective LSPR biosensor for molecular-level glycated albumin detection.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Review
- Dual-Mode Electrochemical Biosensor Based on Gold Nanoparticles/Two-Dimensional MoWSACS applied bio materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A biosensor specifically engineered to detect glycated albumin (GA), a critical biomarker for diabetes monitoring, is presented. Unlike conventional GA monitoring methods, the biosensor herein uniquely employs localised surface plasmon resonance (LSPR) for signal transduction, leveraging a novel fabrication process where gold nanoparticles are deposited on a quartz substrate using flame spray pyrolysis. This enables the biosensor to provide mean glucose levels over a three-week period, correlating with the glycation status of diabetes patients. The sensor's DNA aptamer conjugation selectively binds GA, inducing a plasmonic wavelength shift; resulting in a detection limit of 0.1 μM, well within the human GA range of 20-240 μM. Selectivity experiments with diverse molecules and an exploration of sensor reusability were carried out with positive results. The novelty of the biosensor presented includes specificity, sensitivity and practical applicability; which is promising for enhanced diabetes diagnosis using a rapid and inexpensive process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.